Enter the “Mos for Massey” Social Media Contest!
“Movemeber” is a campaign that encourages men to grow moustaches during the month of November to help raise awareness for testicular cancer, prostate cancer and mental health issues. VCU Massey Cancer Center invites everyone to join the “Movember” movement and help us raise awareness for men’s cancers by taking part in our “Mos for Massey” contest.
Drug combination therapy causes cancer cells to “eat themselves”
Results from a recent preclinical study led by Paul Dent, Ph.D., have shown that a new drug combination therapy being developed at Virginia Commonwealth University Massey Cancer Center effectively killed colon, liver, lung, kidney, breast and brain cancer cells while having little effect on noncancerous cells. The results lay the foundation for researchers to plan a future phase 1 clinical trial to test the safety of the therapy in a small group of patients.
Steven R. Grossman appointed deputy director of Massey
Steven R. Grossman, M.D., Ph.D., has been appointed the deputy director of Virginia Commonwealth University Massey Cancer Center. This new position was added to support the continuation of Massey’s upward trajectory and considerable growth over the last few years. As deputy director, Grossman will lead the planning and development of disease-specific scientific research groups; oversee clinical oncology interactions; and develop strategic initiatives in new multidisciplinary research areas.
An eye on prevention
Cancer screening can improve the length and quality of life, but the average American receives only half of recommended cancer preventive services. Massey researchers will conduct a new study supported by a multi-year, multi-phase grant from the National Institutes of Health (NIH) to measure whether making personal health records with higher functionality available to primary care physicians and patients promotes shared health decision-making and increases the delivery of cancer screening.
Massey first in Richmond to offer cutting-edge therapy for metastatic prostate cancer
VCU Massey Cancer Center is the first cancer care provider in the Richmond metropolitan region to offer radium-223, an innovative, new drug that has been shown to increase survival and quality of life in patients with metastatic castration-resistant prostate cancer (CRPC). Radium-223 is given intravenously once a month for six months. The treatment is considered to be safe and manageable for both patients and providers and is covered by Medicare.